Approved for use through 10/31/2002, CMB 0651-0031
U.S. Patent and Trademark Office: VS. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of findomation unless it contains a valid CMB counted number.

Complete if Known			
Application Number	10/539,672		
Filing Date	June 14, 2005		
First Named Inventor	Cox et al.		
Group Art Unit			
Examiner Name			
Attorney Docket Number	1963.02-9527US		
	Filing Date First Named Inventor Group Art Unit Examiner Name	Application Number 10/539,672 Filing Date June 14, 2005 First Named Inventor Cox et al. Group Art Unit Examiner Name	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No.	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-4,112,073	09-05-1978	Ono	
		US-			
		US-		1	
		US-			
	T	US-			

		FOREIGN P	ATENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document	Publication Date Applicant of Cited MM-DD-YYYY Document		Pages, Columns, Lines,	
Initials*		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			Where Relevant Passages or Relevant Figures Appear	T ⁶
		EP 1 585 497 BI	03-26-2008	Intervet International B.V.		
		-	I			
			+			
		· · · · · · · · · · · · · · · · · · ·				

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Pattern and Trademark Office. Washington, DC 20231. DO NOT SEND FEED OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patterns, P.O. Box 1449, Alexandria, VA. 2231-14450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant,

Applicant's unique citation designation number (potional). *See Kinds Codes of UKSPTO Patter Documents at moving agroups or PMEP 901 (84. **Enter Officer that issued the document, by the two-lefter code (VMD) Standard ST3... *For Apparent petater documents, be in dication of the year of the region of the improve must precede the strial number of the patter document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check must here it fightly handgage Translation is a tracked.

Approved for use through 7/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ed to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO	Complete if Known		
THEODAY A TRONI DIGGE OCUPE	Application Number	10/539,672	
INFORMATION DISCLOSURE	Filing Date	June 14, 2005	
STATEMENT BY APPLICANT	First Named Inventor	Cox et al.	
	Group Art Unit		
(use as many sheets as necessary)	Examiner Name		
Sheet of	Attorney Docket Number	1963 02-9527US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		BREITSCHWERDT et al., Prednisolone at Anti-Inflammatory or Immunosuppressive Dosages in Conjunction with Doxycycline Does Not Potentiate the Severity of Ricketsta inclettati infections in Dogs, Antimicrobial Agents and Chemotherapy, Jan. 1997, pp. 141-47, Vol. 41, No. 1.	
		GELETA et al., Excretion of [³ H]prednisolone in clinically normal and experimentally infected bovine udders, Am. J. Vet. Res., August 1984, Vol. 45, No. 8.	
		ORDEN et al., In Vitro Activities of Cephalosporins and Quinolones against Escherichia coli Strains Isolated from Diarrheic Dairy Calves, Antimicrobial Agents and Chemotherapy, March 1999, pp. 510-13, Vol. 43, No. 3.	
		SHPIGEL et al., Efficacy of Cefquinome for Treatment of Cows with Mastitis Experimentally Induced Using Escherichia coli, J. Dairy Sci., pp. 318-25, Vol. 80.	
		MATSUDA et al., Abstract, Combination Chemotherapy for Klebsiella Mastitis, Journal of Veterinary Medicine, Japan, 1995, pp. 985-88, Vol. 48, No. 12.	
		Summary of Product Characteristics of Product CEPHAGUARD LC, marketing authorization of 2001.	
		Report on prednisolone issued by the "Committee for veterinary medicinal products, EMEA/MRI/629/99-FINAL, published in July 1999.	
		Notice of Opposition in French and Notice of Opposition in English for European patent No. 1 585 497 B1.	
		Opposition response dated July 30, 2009.	

Signature		Considered	00/04/2010
*EXAMINER: Initia	al if reference considered, whether or not citation is in conforman	nw line through citation if not in conformance and not	

Date

/Samira Jean-Jouis/

03/04/2010

considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form absould be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND TEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80.4 1450, Alexandriy, N. 22313-1450.